Fresh from ACG 2025, Dr. David Johnson spotlights four studies poised to reshape GI practice — from colonoscopy quality to breakthroughs in liver and pelvic floor disorders.
One standout analysis linked higher sessile serrated lesion detection rates (SSLDR) to up to 80% lower post-colonoscopy cancer risk, pushing benchmarks beyond the current 6% target. Yet, another nationwide registry revealed major noncompliance with bowel prep guidelines, with over half of patients never returning after inadequate preparation — a “9-1-1 call” for improving colonoscopy follow-up.
Beyond colon cancer, translumbosacral neuromodulation therapy showed dramatic reductions in fecal incontinence episodes, hinting at nerve regeneration potential. Meanwhile, resmetirom, a selective thyroid hormone receptor beta agonist, reversed fibrosis in advanced MASH cirrhosis, with 28% of patients shedding signs of portal hypertension after two years.
Together, these findings mark a pivotal moment in GI — where precision, technology, and persistence could redefine patient outcomes.